Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8666
Peer-review started: April 14, 2021
First decision: June 15, 2021
Revised: June 19, 2021
Accepted: August 30, 2021
Article in press: August 30, 2021
Published online: October 16, 2021
Processing time: 184 Days and 3.4 Hours
Core Tip: Management of diabetes mellitus induced acute complications or treatment-related adverse events is particularly important in critically ill patients. The innovation of continuous glucose monitoring (CGM) helps medical staffs to alert the emergence hyperglycemia and hypoglycemia, which may decrease potential complications in patients in intensive care unit. The major limitation of CGM is the measurement of interstitial glucose levels rather than the real-time blood glucose levels; thus, there will be a time gap in the appropriate treatment of hyperglycemia and hypoglycemia in patients. The European Union approved a state-of-art artificial intelligence directed loop system coordinated by CGM and a continuous insulin pump for diabetes control, providing a practical way to prevent acute adverse glycemic events related to antidiabetic therapy in critically ill patients.
